News

Filter

NICE says ‘yes’ to Remicade, Humira and Simponi for ulcerative colitis

NICE says ‘yes’ to Remicade, Humira and Simponi for ulcerative colitis

12-12-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has issued…

AbbVieGastro-intestinalsHumiraMerck & CoPharmaceuticalPricingRegulationRemicadeSimponi InjectionUK

NICE opens consultation on three drugs for chronic bowel condition

NICE opens consultation on three drugs for chronic bowel condition

24-09-2014

Three drugs to treat ulcerative colitis, a chronic bowel condition, have not been proven to be more cost…

AbbVieGastro-intestinalsHumiraMerck & CoPharmaceuticalPricingRegulationRemicadeSimponi InjectionUK

Approval of Takeda’s Entyvio marks “historic change” for IBD treatment

Approval of Takeda’s Entyvio marks “historic change” for IBD treatment

03-06-2014

The recent approval of Japanese drug major Takeda’s Entyvio (vedolizumab) by the European Medicines…

EntyvioGastro-intestinalsHumiraMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionStelaraTakeda Pharmaceutical

Global ulcerative colitis market to reach $6.6 billion by 2022

Global ulcerative colitis market to reach $6.6 billion by 2022

14-02-2014

The global ulcerative colitis market value will increase steadily over the coming years, increasing from…

AbbVieEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionTakeda Pharmaceuticals

US FDA approves Janssen's Simponi to treat ulcerative colitis

16-05-2013

The US Food and Drug Administration late yesterday (May 15) approved a new use for Johnson & Johnson…

BiotechnologyGastro-intestinalsInflammatory diseasesJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

US gastroenterologists' attitudes to prescribing for Crohn's disease and ulcerative colitis

09-09-2012

When evaluating the most important attributes for emerging therapies for Crohn's disease (CD) and ulcerative…

BiotechnologyGastro-intestinalsHumiraMarkets & MarketingNorth AmericaRemicadeSimponi Injectionvedolizumab

Ulcerative colitis drug market to reach $3 billion by 2020

02-05-2012

The ulcerative colitis drug market will experience moderate growth over the next decade, increasing from…

Gastro-intestinalsHumiraMarkets & MarketingPharmaceuticalRemicadeSimponi Injectiontofacitinibvedolizumab

COMPANY SPOTLIGHT

Menarini

Back to top